NOVAVAX INC (NVAX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NVAX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVAX | Private Investor; Chairman of the Board; CHAIRMAN OF THE BOARD; Member | 60 | ["Industry Experience","Executive Leadership","Accounting, Financial or Investment Experience","Cybersecurity/IT/AI","Public Company Board","Chief Executive Officer and Chief Investment Officer at Sphinx Mountain Capital LLC","Private investor at Mott Family Capital","General Partner at New Enterprise Associates","President and Chief Executive Officer at MedImmune","Served in various senior roles including Chief Operating Officer and Chief Financial Officer","More than three decades of global management, board, and investment experience","presiding at all meetings of the Board","advising Board committee chairs","serving as a liaison between the Board and senior management team","mentoring and advising the chief executive officer","providing an extensive network of contacts","reporting regularly to the Board"] | ["Compensation","Research & Development","Capital Allocation","Research and Development Committee"] | 2026 |
Biography sourced from the proxy statement filing.
CHAIRMAN OF THE BOARD AGE 66 INDEPENDENT DIRECTOR SINCE 2018 COMMITTEES Compensation Nominating & Corporate Governance Mott Family Capital Private investor (2020 to 2025) New Enterprise Associates General Partner (2008 to 2020) MedImmune President and Chief Executive Officer, Vice Chairman (2000 to 2008), during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion Served in various senior roles, including Chief Operating Officer and Chief Financial Officer (1992 to 2000) OTHER PUBLIC COMPANY BOARDS Chairman, Ardelyx (Nasdaq: ARDX) EDUCATION Bachelor of Arts, Dartmouth College KEY SKILLS AND QUALIFICATIONS Mr. Mott is well-suited to serve on our Board due to his more than three decades of global management, board, and investment experience across numerous private and public biopharmaceutical companies, as well as his extensive experience building, leading, and financing biopharmaceutical companies which adds significant value to our Board.